Go to the profile of Carmen Ramirez

Carmen Ramirez

Sales Account Executive, Springer Nature
  • Springer Nature
  • +1-212-451-8472
  • Editors
  • United States of America
Go to the profile of Hocvienthammyprana
Hocvienthammyprana

học viện thẩm mỹ prana, học viện thẩm mỹ prana

Go to the profile of Serafim B. Tavares
Serafim B. Tavares

Independent Worker, Service Provider, [ (...) (e.g. Accountant / Auditor / Among others professional titles)], SBT, Serafim Bastos Tavares (SBT)

Go to the profile of Wilson Gbedema
Wilson Gbedema

Teaching Assistant, University of Cape Coast

Go to the profile of Professor Dr. Sorush Niknamian
Professor Dr. Sorush Niknamian

Member of US Army Surgeons and Federal Health Professionals, US Army Forces, USA, Weston A Price Foundation (WAPF)/Board Member

Cancer Biology Scientist
Go to the profile of Sorush Niknamian
Sorush Niknamian

Cancer Researcher, Liberty university

Go to the profile of Mekhled Alzaza
Mekhled Alzaza

Research Scientist, NA

Go to the profile of Charles Thiede
Charles Thiede

CEO & Co-Founder, Zapnito

My background is in technology, professional services and digital media. I co-founded Zapnito due to a number of related observations from my time in these sectors: 1) the social web is creating a huge amount of noise 2) expertise that brands have built up over decades is being drowned out and hidden from those that need it 3) these brands are therefore losing their audience to often undeserving and unhelpful sources, and 4) people are finding it harder to access the expertise that they truly value. I therefore decided to create Zapnito, a white-label platform to help trusted brands reclaim their audiences via expert-driven knowledge networks.
Go to the profile of Alexandro Nunes
Alexandro Nunes

Doutorando em Materiais para Engenharia na Universidade Federal de Itajubá

Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

TAHO is a specialty pharma focus on identifying, and developing new products that offer better therapeutic options to patient populations that may be under served. By utilizing company’s technology platform, it offers service niches in drug delivery. TAHO’s transdermal delivery platform allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. It transform the patient care by: . Continuous delivery, safe, reliable, and pain-free application . Improved convenience, tolerability, and dosing . Flexible drug administration TAHO’s transmucosal delivery system, delivery the drug as a thin film, an evolution from tablets or capsules. It is a better patient care with: . Convenient dosing, no water needed . No risk of choking . Taste masking Let TAHO be your partner for innovative solutions and diverse your product pipeline
ImmuneOncia was established as a joint venture between Sorrento Therapeutics, USA and Yuhan Corporation, Korea, focusing on immuno-oncology and aims to bring safe, effective immunotherapies to patients worldwide.
Glycostem has developed a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from various sources like umbilical cord blood (UCB), bone marrow (BM) or mobilized peripheral blood (mPB). Within the last years, Glycostem's platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells or antigen presenting cells such as dendritic cells. The technology platform is based on the use of closed bioreactor systems in combination with a proprietary synthetic cell culture medium (GBGM - Glycostem Basal Growth Medium) and a patented combination of growth factors. Glycostem has treated 10 elderly and fragile AML patients in a phase I setting with excellent safety profile and strong indication of clinical efficacy. Year 1 survival data showed 80% compared to population data showing 35%. By late 2019 Glycostem expects to have GMP approved facilities utilising closed system technology resulting is the lowest possible production cost with off the shelf products for our pivotal clinical trial starting early 2020.
Forendo Pharma is a drug development company aiming for novel treatment solutions for endometriosis patients, by using tissue-specific hormone inhibitors, to rebalance local estrogen metabolism. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels. The company was founded in 2013 by leading academic endocrinology professionals and Finnish drug development pioneers. Forendo is supported by strong investors with broad international contacts: Novo Seeds, Karolinska Development, Novartis Venture Fund, Merck Ventures and Innovestor. T he company pipeline includes HSD17B1 inhibitor (preclinical) for the treatment of endometriosis; Dual HSD inhibitor (discovery) for the treatment of endometriosis, with potential for other endocrinological diseases; Fispemifene (phase 2), novel SERM for the treatment of male urological conditions.
IsoPlexis is a life sciences company committed to advancing precision medicine in the fight against cancer, autoimmune and infectious diseases. The IsoPlexis single cell detection platform isolates single immune cells and analyzes their full functional response to assess the effectiveness of therapeutics and to predict patient clinical response. The newly introduced Isolight® Next Generation Single Cell Analysis system is a versatile precision engineering platform designed to understand and characterize differences among single cells, mapping thousands of cells per sample, to reveal full functional profiles and polyfunctionality among cell subsets to determine patient response and product quality.
YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologies by its founders. With this platform YUMAB generates antibody candidates with natural, close to germ-line sequences for lowest immunogenicity and with pre-designed properties (e.g., interspecies X-reactivity, large epitope coverage or targeted epitopes). The candidates are highly developable into several antibody drug formats like full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides customized solutions from target discovery and production, personalized antibody libraries, optimized antibody discovery strategies (also directly on cells) to close to germline antibody engineering and lead development with high success-rates even to difficult targets like GPCRs. YUMAB offers flexible business models from fee-for-service solutions to collaborative projects. Services are not limited to therapeutic development – it also contains recombinant antibody development for next-generation research and for diagnostic applications.
BIOCAD is Russia's leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the world's few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCAD`s medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients. BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential: Acute myeloid leukaemia (AML); Advanced non-small-cell lung cancer (NSCLC); Triple negative breast cancer (TNBC) The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules. BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic and diagnostic agents for the treatment and monitoring of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. The company currently has two candidates in development. One targeting HPV for cervical cancer and one against Survivin/IAP for a range of solid tumours.